Acelyrin, Inc. (SLRN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Mina Kim J.D. | CEO & Director | 906.64k | -- | 1974 |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer | 679.64k | -- | 1967 |
| Mr. Tyler Marciniak | Vice President of Investor Relations, Communications & Corporate Operations | -- | -- | -- |
| Mr. K. Amar Murugan J.D. | Chief Legal Officer | -- | -- | 1976 |
| Ms. Kelly Chow | Chief People Officer | -- | -- | -- |
| Mr. Kenneth A. Lock | Chief Commercial Officer | -- | -- | 1974 |
| Ms. Patricia A. Turney | Chief Technical Operations Officer | -- | -- | 1967 |
Acelyrin, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 83
Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Corporate Governance
Upcoming Events
August 11, 2025 at 8:00 PM UTC - August 19, 2025 at 8:00 PM UTC
Acelyrin, Inc. Earnings Date
Recent Events
May 1, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
April 29, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
March 25, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions